Crohn's Disease News and Research

Latest Crohn's Disease News and Research

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

8 Aug 2012

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

7 Aug 2012

'Fight' between bacteria in the intestines linked to chronic disease

Results from a study conducted at Georgia State University suggest that a "fight" between bacteria normally living in the intestines and the immune system, kicked off by another type of bacteria, may be linked to two types of chronic disease.

3 Aug 2012

Freiburg scientist receives ERC Starting Grant for NutrImmune project

The microbiologist and immunologist Prof. Dr. Andreas Diefenbach, Institute of Medical Microbiology and Hygiene, University of Freiburg Medical Centre, has been awarded a European Research Council "Starting Grant" for his project "NutrImmune". The ERC Starting Grant is one of Europe's most prestigious grants for young investigators.

1 Aug 2012

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

More than one billion people in poor countries are starving, and malnutrition remains a major problem even in rich countries, making it a leading cause of death in the world. For over a hundred years, doctors have known that a lack of protein in the diet or low levels of amino acids, the building blocks of proteins, can lead to symptoms like diarrhoea, inflamed intestines and other immune system disorders, which weaken the body and can be fatal. However, the molecular mechanism which explains how malnutrition causes such severe symptoms has been largely unexplored.

26 Jul 2012

Giving patients a new immune system can cure Crohn's disease

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

25 Jul 2012

Study represents new use of bone marrow transplantation

24 Jul 2012

Short-term infection with intestinal worms may provide long-term protection against TID

Short-term infection with intestinal worms may provide long-term protection against type I diabetes (TID), suggests a study conducted by William Gause, PhD, and colleagues at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School.

20 Jul 2012

Smoking offers no benefits in IBD prevention

Smoking increases the risk for Crohn’s disease but not ulcerative colitis, the results of the largest prospective study of the link between inflammatory bowel disease and the habit confirm.

19 Jul 2012

Researchers discover HVEM’s unknown role in fighting off E. coli infections

Despite ongoing public health efforts, E. coli outbreaks continue to infiltrate the food supply, annually causing significant sickness and death throughout the world. But the research community is gaining ground. In a major finding, published today in the scientific journal Nature, researchers from the La Jolla Institute for Allergy & Immunology have discovered a molecule's previously unknown role in fighting off E. coli and other bacterial infections, a discovery that could lead to new ways to protect people from these dangerous microorganisms.

16 Jul 2012

EGF helps prevent inflammation-induced cancer

Epidermal growth factor (EGF) is a protein that normally regulates intestinal healing. However, biological therapies, like EGF, also may pose the risk of increasing the possibility of cancer. Philip Dubé, PhD, and Brent Polk, MD, both of the Saban Research Institute of Children's Hospital Los Angeles have demonstrated that in preclinical models, EGF encourages healing and provides powerful anti-inflammatory properties that prevent inflammation-induced cancer.

10 Jul 2012

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Although some have suggested that patients receiving medication for immune-mediated diseases such as rheumatoid arthritis or psoriasis may be at increased risk of herpes zoster (HZ; shingles) shortly after receipt of the vaccine, an analysis that included nearly 20,000 vaccinated Medicare beneficiaries finds that the live zoster vaccine is not associated with an increased risk of HZ shortly after vaccination in patients currently treated with biologics, and that it is associated with a significantly reduced longer-term risk of HZ in patients with an immune-mediated disease, according to a study in the July 4 issue of JAMA.

4 Jul 2012

Study illuminates key step in the journey of inflammation-producing immune cells

Like detectives seeking footprints and other clues on a television "whodunit," science can also benefit from analyzing the tracks of important players in the body's molecular landscape. Klaus Ley, M.D., a scientist at the La Jolla Institute for Allergy & Immunology, has done just that and illuminated a key step in the journey of inflammation-producing immune cells.

2 Jul 2012

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Dr. Grace McCarthy, Chairman of the Board of The Foundation for Children with Intestinal and Liver Disorders (CH.I.L.D), today announced an important new partnership with the Canadian Institutes of Health Research (CIHR) to fund the creation of the Canadian Children Inflammatory Bowel Disease Network: A Joint Partnership of CIHR and the CH.I.L.D. Foundation.

30 Jun 2012

Young inflammatory bowel disease patients have low bone mass

Children and adolescents with inflammatory bowel disease have significantly lower bone mineral density than their healthy peers, even after adjusting for pubertal delay, Finnish researchers report.

29 Jun 2012

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could - paradoxically - shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children's Center and the Center for TB Research.

29 Jun 2012

Young inflammatory bowel disease patients have low bone mass

Children and adolescents with inflammatory bowel disease have significantly lower bone mineral density than their healthy peers, even after adjusting for pubertal delay, Finnish researchers report.

28 Jun 2012

TB research finds body’s own response helps TB bacteria survive

Inhibiting a key immune response in mice during initial multi-drug treatment for tuberculosis could — paradoxically — shorten treatment time for the highly contagious lung infection according to new research from Johns Hopkins Children’s Center and the Center for TB Research. Shorter duration of drug therapy is key, researchers say, to increase treatment compliance for the growing global health threat posed by the disease.

28 Jun 2012

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

Infinity Pharmaceuticals, Inc. today reported preclinical data for IPI-145, the company's oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data demonstrate potent PI3K-delta and -gamma inhibition in biochemical, cellular and whole blood assays and activity in multiple preclinical models of inflammatory disease, including rheumatoid arthritis and asthma.

28 Jun 2012

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).

22 Jun 2012

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

Adalimumab effective in maintaining remission in pediatric patients with Crohn's disease

'Fight' between bacteria in the intestines linked to chronic disease

Freiburg scientist receives ERC Starting Grant for NutrImmune project

Molecular explanation for increased susceptibility to intestinal inflammation in malnutrition

Giving patients a new immune system can cure Crohn's disease

Study represents new use of bone marrow transplantation

Short-term infection with intestinal worms may provide long-term protection against TID

Smoking offers no benefits in IBD prevention

Researchers discover HVEM’s unknown role in fighting off E. coli infections

EGF helps prevent inflammation-induced cancer

Live zoster vaccine associated with reduced risk of HZ in patients with immune-mediated diseases

Study illuminates key step in the journey of inflammation-producing immune cells

CIHR and CH.I.L.D. create Canadian Children Inflammatory Bowel Disease Network

Young inflammatory bowel disease patients have low bone mass

Inhibiting immune response during initial multi-drug therapy could speed TB treatment time

Young inflammatory bowel disease patients have low bone mass

TB research finds body’s own response helps TB bacteria survive

Data from Infinity’s IPI-145 pre-clinical study on inflammatory diseases

European CHMP adopts positive opinion for teduglutide to treat short bowel syndrome

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in